|
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES |
||||
|
|
|
|||
|
1. Identity of the issuer or the underlying issuer |
Alliance Pharma plc |
|||
|
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
|
An acquisition or disposal of voting rights |
√ |
|||
|
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
|
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
|
An event changing the breakdown of voting rights |
|
|||
|
Other (please specify): |
CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT PLACING.
|
√ |
||
|
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
|||
|
4. Full name of shareholder(s) |
Registered Holder:
BNY Norwich Union Nominees Limited 4,504,148*
Chase (GA Group) Nominees Limited 38,042,725*
*denotes direct interest
Chase Nominees Limited 1,406,658
|
|||
|
5. Date of the transaction and date on |
17 December 2015 |
|||
|
6. Date on which issuer notified: |
18 December 2015 |
|||
|
7. Threshold(s) that is/are crossed or |
7% to 9% Change at Direct Interest Level (Box 8A) |
|||
|
8. Notified details: |
|||||||||||
|
A: Voting rights attached to shares |
|||||||||||
|
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||
|
Number |
Number |
Number |
Number of voting |
% of voting rights |
|||||||
|
Direct |
Direct |
Indirect |
Direct |
Indirect |
|||||||
|
Ordinary Shares |
22,533,531* |
22,533,531* |
43,953,531 |
42,546,873 |
1,406,658 |
9.09% |
0.30% |
||||
|
|
|||||||||||
|
* Includes Right to Recall Loaned Shares (1,500,000)
|
|||||||||||
|
B: Qualifying Financial Instruments |
|||||||||||
|
Resulting situation after the triggering transaction |
|||||||||||
|
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||
|
|
|
|
|
|
|||||||
|
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments |
||||||
|
Resulting situation after the triggering transaction |
||||||
|
Type of financial |
Exercise price |
Expiration date |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights
|
|
|
RIGHT TO RECALL LOANED SHARES |
N/A |
N/A |
N/A |
1,080,000*
*Direct Interest
|
Nominal |
Delta |
|
0.23% |
|
|||||
|
Total (A+B+C) |
|
|
Number of voting rights |
Percentage of voting rights |
|
45,033,531 |
9.62% |
|
9. Chain of controlled undertakings through which the voting rights and/or the |
||
|
The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
|
||
|
|
||
|
Proxy Voting: |
||
|
10. Name of the proxy holder: |
See Section 4 |
|
|
11. Number of voting rights proxy holder will cease |
|
|
|
12. Date on which proxy holder will cease to hold |
|
|
|
|
||
|
|
17 December 2015.
|
|
|
14. Contact name: |
Neil Whittaker, Aviva plc |
|
|
15. Contact telephone number: |
01603 684420 |
|